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 Otterbein University, Westerville, Ohio  
Early Onset Alzheimer’s Disease in Individuals with Down Syndrome: Explored Theories of Pathophysiology 
. 
     This presentation is a focus on some of 
the theories of the pathophysiology of 
early-onset Alzheimer’s Disease (AD) in 
individuals with Down Syndrome (DS). 
Down Syndrome, a genetic condition 
where an individual has a partial or full 
extra chromosome 21, is the most 
common chromosomal condition in the 
United States (National Down Syndrome 
Society (NDSS), 2012).  Average life 
expectancy for individuals with DS has 
vastly increased in the last thirty years 
from age 25 to age 60 (NDSS, 2012).  The 
extra chromosome genetically makes 
individuals with DS predisposed to certain 
conditions, including early onset dementia 
and AD, therefore as their life expectancy 
increases, so does their risk of developing 
this disease.  Early-onset AD is 
characterized by having AD by the age 65.  
The purpose of this presentation is to aid 
practitioners in having a better 
understanding of the disease process in 
order to provide appropriate and timely 
diagnosis and treatment for this growing 
population. 
     Alzheimer’s Association (2014) describes the early 
presentation of AD as difficulty in remembering newly 
learned information, with advances stages potentially 
presenting with mood or behavior changes, 
disorientation, more severe memory loss, and difficulty 
in walking, speaking, and swallowing.  In individuals 
with DS, other symptoms of AD may appear first, 
especially behavior and mood changes.  Ball, Holland, 
Watson and Huppert (2011) state that “preclinical 
stages of AD , as it develops in people with DS, are 
marked by changes in personality and behavior, 
associated with a specific impairment in the cognitive 
functions subserved by the frontal lobes” (p.321).  
Diagnosis in individuals with DS can also be difficult 
because the tasks performed in standard testing may 
not be possible for these individuals to perform.  
The Alzheimer’s Association (2014) provides the 
following early symptoms of AD in individuals with DS: 
• Reduced interest in being sociable, conversing or 
expressing thoughts 
• Decreased enthusiasm for usual activities 
• Decline in ability to pay attention 
• Sadness, fearfulness or anxiety 
• Irritability, uncooperativeness or aggression 
• Restlessness or sleep disturbances 
• Seizures that begin in adulthood 
• Changes in coordination and walking 
• Increased noisiness or excitability 
Pathophysiological 
Processes 
      All individuals with DS, by the age of 40, 
will develop neuropathological changes of AD, 
including the hallmark signs of amyloid 
plaques and neurofibrillary tangles (NFTs) 
(Head et. Al, 2011).  This neuropathological 
presentation has been attributed to the 
triplication and overexpression of the gene for 
amyloid precursor protein (APP), which is 
located on chromosome 21 (Jones et. al, 2011).  
This does not count for the entire picture, so 
other contributing factors must be explored.  
Signs and Symptoms Underlying Pathophysiology 
      AD is not completely understood, including in individuals with 
DS, however there are some known processes, including amyloid 
plaques and neurofibrillary tangles, and there are several additional 
theories to explain the processes of AD and early-onset AD beyond 
that.  It is known that all individuals with DS have a partial or full 
triplication of chromosome 21, as well as amyloid plaques and NFTs 
by the age of 40.  The following are examples of suggested theories 
to AD, AD in DS and early-onset AD: 
• Head et al. (2011) state that the amyloid plaques contain the 
amyloid Beta peptide that is derived from a longer precursor 
protein, amyloid Beta protein precursor, the gene for which is 
on chromosome 21.  Overexpression by triplication of this 
chromosome is suggested to be the cause of the excessive 
amyloid plaques in individuals with DS. 
• Serano-Pozo, Frosch, Masliah, and Hyman (2011) state that 
neuropathological changes that occur in any AD include 
abundant amyloid plaques, neurofibrillary tangles along with 
neuropil threads, dystrophic neurites containing 
hyperphosphorylated tau that are accompanied by astroglials 
and microglial cell activation leading to the characteristic 
losses of neurons, nueropils, and synaptic elements.  They 
also argue the neuroanatomical changes begin to accumulate 
ten years or more prior to the dementia diagnosis, making 
early detection of these changes important for early 
treatment.  
• Jones, Margallo-Lana, Prasher, and Ballard (2008) suggest that 
the pathology consists of amyloid plaques, and NFTs with 
hyperphosphorylated tau in the form of paired helical 
elements.  They state that a tetranucleotide repeat in intron 7 
of APP has been associated with an earlier onset of dementia 
(Jones, Margallo-Lana, Prasher, and Ballard, 2008).  The 
relevance of this to DS is that this is located on chromosome 
21, which is triplicated in DS.  
• Jones et al. do a later study that further discusses APP.  The 
study states that APP is expressed in DS at levels four to five 
times higher than the general population (Jones et.al, 2011).  
They claim that the regulators of APP expression are also 
located on chromosome 21.  The processing of APP results in 
production of beta amyloid which is deposited extracellularly 
in the brain, found as a core disease feature in people with AD 
(Jones et al., 2011).  
• Wilcock and Griffin (2013) state that overexpression of APP 
and S100B and resultant overexpression of the pluripotent 
neuroinflammatory cytokine IL-1 end in multiple neural 
results that is characterized by gliosis-related 
neuroinflammation and the neuropathological changes of AD. 
S100B is an astrocyte-derived cytokine, encoded by 
chromosome 21 and is markedly elevated through life in 
individuals with DS. 
• Ball, Holland, Watson and Huppert (2010) also explore the 
effects of SB100 in that it is involved in mediating growth of 
serotonin neurons.  The study also revealed that individuals 
with DS who were on antidepressants was significantly 
associated with better performance in working memory tests.   
• Coskun et al. (2010) proposed that etiology  of premature 
dementia is the result of an underlying mitochondrial 
dysfunction resulting in energetic deficiency, increased 
oxidative stress, altered Calcium regulation, and predication 
to cell death through activation of mtPTP, resulting in a loss of 
neuronal process and neurons.  
Significance of 
Pathophysiology 
     It is known that AD is partially a 
resultant of amyloid plaques and NFTs, 
and that individuals with DS will acquire 
both of these before the age of 40. 
Several studies have been done to suggest 
that there are other factors that play a 
role in early onset AD.  It has been 
reported that early-onset AD in a general 
population is of the familial type, 
suggesting that the problem lies 
somewhere within genes.  The 
significance of the pathophysiology in 
individuals with DS is that the triplication 
of chromosome 21 causes overexpression 
of proteins and other materials that lead 
to amyloid plaques and NFTs at an early 
age.  The further study of individuals with 
DS can hold the key to answer questions 
that are still unanswered about the 
pathophysiology of early-onset AD and AD 
in general.  Further studies could also 
explore the potential effects of selective 
serotonin reuptake inhibitors.  
References Implications for 
Nursing Care 
     Since it is known that all individuals 
with DS will have neuropathological 
features of AD, it is pertinent that health 
care professionals monitor for signs of 
cognitive change at an early age.  A 
baseline cognitive and behavioral 
assessment should be performed on the 
DS individual by the age of 35 with an 
annual screening starting at age 40. Early 
signs of dementia and AD often go 
unnoticed in individuals with DS due to 
their atypical presentation of behavioral 
changes instead of memory impairment.  
Behavioral changes are also often 
attributed in the DS population as part of 
their developmental disability.  Whitwan, 
McBrien, and Broom (2010) developed a 
standardized screening checklist to help 
health care professionals know when to 
make a referral for a dementia 
assessment for individuals with DS and 
other developmental disabilities.  
Conclusion 
     Every individual with DS will have the AD hallmark diagnostic criteria of amyloid 
plaques and NFTs by the age of 40.  The triplication of chromosome 21 that is 
characteristic of DS causes overxpression of genetic materials that contribute to this.  
This makes it evident that chromosome 21 is a primary factor that contributes to the 
development of AD.  Further focused studies on the role that chromosome 21 plays 
in individuals with early onset AD can potentially be used to develop targeted drugs 
to stop of slow down the process.   
Brain Scan Comparison of Individuals with DS and AD,  
Ghose, 2011.  
Epidemiology  
     As previously discussed, all individuals 
with DS develop neuropathological changes 
of AD.  Mean age of clinical diagnosis of AD in 
DS individuals is 51+/- 6 (Alvarez, Hoffmann, 
Hauser & Talavera 2014).  A review of studies 
showed that 10-25% of patients had AD when 
aged 40-49 years, 20-50% had AD when aged 
50-59 years, and 60-75% had AD when older 
than 60 years (Alvarez, Hoffmann, Hauser & 
Talavera, 2014) 
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